Advertisements



Here"s Why Sarepta Therapeutics Jumped 17% in September

Lifting of a clinical hold continued the momentum......»»

Category: topSource: foxnewsOct 11th, 2018

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaMay 12th, 2019

Jim Cramer Gives His Opinion On Sarepta, Blackstone, Tractor Supply And More

On CNBC's "Mad Money Lightning Round", Jim Cramer said he wouldn't buy Sarepta Therapeutics Inc (NASDAQ: SRPT) because it's a one-drug company. read more.....»»

Category: blogSource: benzingaApr 26th, 2019

What CRISPR Has Planned for Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics shares jumped on Tuesday after the firm announced that the FDA has granted Fast Track Designation for its treatment for transfusion-dependent beta thalassemia......»»

Category: blogSource: 247wallstApr 16th, 2019

Here"s Why Sorrento Therapeutics Soared 134% in March

The early-stage biotech jumped without any significant news......»»

Category: topSource: foxnewsApr 9th, 2019

What’s Next for Sangamo After This Hemophilia Study

Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer......»»

Category: blogSource: 247wallstApr 2nd, 2019

What"s Wrong With Sarepta Therapeutics?

What"s Wrong With Sarepta Therapeutics?.....»»

Category: topSource: seekingalphaApr 1st, 2019

Sarepta Therapeutics stock up 3.4% after Phase 3 interim analysis shows positive results for DMD drug

Shares of Sarepta Therapeutics rose 3.4% in premarket trade Thursday after the company announced positive results from a Phase 3 interim a.....»»

Category: topSource: marketwatchMar 28th, 2019

What’s Next for Axsome Therapeutics After This FDA Approval

Axsome shares jumped on Wednesday after the firm gave an update from the FDA regarding its AXS-05 for the treatment of major depressive disorder......»»

Category: blogSource: 247wallstMar 27th, 2019

UPDATE: Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drug

Axsome Therapeutics Inc. shares jumped 13% in premarket trade Wednesday, after the U.S. Food and Drug Administration granted breakthrough therapy designation to a treatment for major depressive disorder. The designation, given to the comp.....»»

Category: topSource: marketwatchMar 27th, 2019

Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drug

Axsome Therapeutics Inc. shares jumped 7% in premarket trade Wednesday, after the U.S. Food and Drug Administration granted breakthrough therapy designation to a treatment for major depressive disorder. The designation, given to the comp.....»»

Category: topSource: marketwatchMar 27th, 2019

Is Sarepta Therapeutics a Good Gene Therapy Stock to Buy Now?

It's hard not to get excited about this company's experimental gene therapy for Duchenne muscular dystrophy......»»

Category: topSource: foxnewsMar 26th, 2019

Sarepta Therapeutics Breaks Below 200-Day Moving Average - Notable for SRPT

Market News Video.....»»

Category: topSource: redinewsMar 15th, 2019

June 15th Options Now Available For Sarepta Therapeutics (SRPT)

Stock Options Channel.....»»

Category: topSource: redinewsApr 14th, 2018

43 Stocks Moving In Wednesday"s Mid-Day Session

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 69 percent to $13.38. read more.....»»

Category: blogSource: benzingaMay 2nd, 2018

Sarepta Therapeuticals shares down 5% after company misses Q1 expectations

Sarepta Therapeutics Inc. shares fell nearly 5% late Thursday after the biopharma company reported a wider-than-expected adjusted first-quarter loss and sales also missed targets. Sarepta said it lost $.....»»

Category: topSource: marketwatchMay 3rd, 2018

Sarepta Therapeutics" (SRPT) CEO Doug Ingram on Q1 2018 Results - Earnings Call Transcript

Sarepta Therapeutics" (SRPT) CEO Doug Ingram on Q1 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaMay 4th, 2018

Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress

Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates. Sarepta Therapeutics, Inc. SRPT incurred a loss o.....»»

Category: dealsSource: nytMay 4th, 2018

Nationwide Children"s gene therapy spinoff inks option to be acquired by Sarepta

Sarepta Therapeutics Inc. has invested up to $105 million in the latest gene therapy spinoff from Nationwide Children's Hospital – and signed an option to acquire the company for an undisclosed but higher amount if clinical trial results are promis.....»»

Category: topSource: bizjournalsMay 8th, 2018

Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More

The futures traded just a touch higher Friday morning as the market continued to digest some big gains from the past two weeks. Stocks took off once again yesterday when the inflation numbers were........»»

Category: blogSource: 247wallstMay 11th, 2018

33 Stocks Moving In Wednesday"s Mid-Day Session

Gainers Cara Therapeutics, Inc. (NASDAQ: CARA) shares jumped 28.5 percent to $14.91 in reaction to a new licensing agreement with Europe-based Vifor Pharma. .....»»

Category: topSource: moneycentralMay 23rd, 2018